AMENDED SET OF CLAIMS

Please amend the claims as follows:

1. An orally administrable composition containing nanoparticles with the particle

size of 500 nm or less, comprising

0.1-30 0.1 to 30 weight% of a complex of a charged water-soluble drug and a

counter-ion substance in which the charged water-soluble drug is ionically bonded with the

counter-ion substance, wherein said counter-ion substance is an anionic compound selected from

the group consisting of sodium salt of C₈₋₁₈ fatty acid, sodium salt of bile acid, sodium alginate,

and sodium carboxymethylcellulose, or a cationic compound selected from the group consisting

of carnitine salt, benzalkonium chloride and cetrimide,

0.5~80 0.5 to 80 weight% of a lipid,

0.5-80 0.5 to 80 weight% of a polymer, and

1-80 1 to 80 weight% of an emulsifier,

wherein the weight ratio of said lipid and said polymer is in the range of 1:0.05-3 1:0.05

· to 3.

2. (Original) The composition of Claim 1, wherein 70% or more of the water-soluble

drug is entrapped in the nanoparticles.

Amendment dated August 20, 2008

Reply to Office Action of April 23, 2008

3. (Currently Amended) The composition of Claim 1, wherein 80% or more of the

Docket No.: 1599-0331PUS1

charged water-soluble drug is retained in the presence of nanoparticle when the composition is

mixed with pancreatin.

4. (Currently Amended) The composition of Claim 1, wherein the charged water-

soluble drug is a protein/peptide drug selected from the group consisting of insulin.

erythropoietin, calcitonin, growth hormone, interferon, and somatostatin.

5. (Withdrawn - Currently Amended) The composition of Claim 1, wherein the charged

water-soluble drug is one charged in water selected from the group consisting of heparin, cepha

antibiotic, sodium alendronate, sodium etidronate, and sodium pamidronate.

6. (Cancelled).

7. (Currently Amended) The composition of Claim 1 Claim 6, wherein the sodium salt

of fatty acid is selected from the group consisting of sodium oleate, sodium lauryl sulfate,

3

sodium caproate, and sodium laurate.

8. (Cancelled).

JTE/CAM/aee

Amendment dated August 20, 2008

Reply to Office Action of April 23, 2008

Docket No.: 1599-0331PUS1

9. (Currently Amended) The composition of Claim 1, wherein the molar ratio of the

charged water-soluble drug and the counter-ion substance is in the range of 1:0.1-20 1:0.1 to 20.

10. (Currently Amended) The composition of Claim 9, wherein the molar ratio of the

charged water-soluble drug and the counter-ion substance is in the range of 1:3-10 1:3 to 10.

11. (Currently Amended) The composition of Claim 1, wherein the weight ratio of the

lipid and the polymer is in the range of 1:0.2-1 1:0.2 to 1.

12. (Original) The composition of Claim 1, wherein the lipid is an aliphatic alcohol

selected from the group consisting of monoglyceride, diglyceride, propyleneglycol fatty acid

ester, glycerol fatty acid ester, cetostearyl alcohol, cetyl alcohol, and mixtures thereof.

13. (Original) The composition of Claim 1, wherein the polymer is selected from the

group consisting of methacrylic acid copolymer, hydroxypropyl methylcellulose phthalate,

hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, shellac, chitosan,

hydroxypropyl methylcellulose and its derivative, ethylcellulose, methylcellulose,

polyvinylalcohol, sodium alginate, carbomer, and mixtures thereof.

14. (Original) The composition of Claim 1, wherein the emulsifier is selected from the

4

JTE/CAM/aee

Amendment dated August 20, 2008

Reply to Office Action of April 23, 2008

group consisting of polyoxyethylene polyoxypropylene copolymer, polyethyleneglycol alkyl

ether, polyoxyethylene castor oil, polyoxyethylene sorbitan fatty acid ester, transesterification

product of natural vegetable oil triglyceride and polyalkylene polyol, glycerol fatty acid ester,

vitamin E polyethyleneglycol succinate, lecithin, sodium lauryl sulfate, bile acid and its

derivative, and mixtures thereof.

15. (Currently Amended) The composition of Claim 1, further comprising 50 weight%

or less of a solubilizing agent.

16. (Currently Amended) The composition of Claim 15, wherein the solubilizing agent

is selected from the group consisting of C_{1-8} C₁₋₈ alcohol, dimethylsulfoxide, dichloromethane,

toluene, propyleneglycol, polyethyleneglycol, and 12-hydroxystearate.

17. (Currently Amended) The composition of Claim 1, further comprising 0.1-30 0.1 to

30 weight% of a cryoprotective agent.

18. (Original) The composition of Claim 17, wherein the cryoprotective agent is

selected from the group consisting of glucose, mannitol, sorbitol, trehalose, amino acid, albumin,

and mixtures thereof.

JTE/CAM/aee

Docket No.: 1599-0331PUS1

5

Amendment dated August 20, 2008

Reply to Office Action of April 23, 2008

19. (Currently Amended) The composition of Claim 1, wherein the particle size of the

Docket No.: 1599-0331PUS1

nanoparticles is in the range of 20-300 20 to 300 nm.

20. (Withdrawn - Currently Amended) A method for preparing the orally administrable

nanoparticle composition of Claim 1, comprising the steps of:

(a) ionically bonding a charged water-soluble drug with a counter-ion substance to form

a complex of the water-soluble drug and the counter-ion substance, wherein said counter-ion

substance is an anionic compound selected from the group consisting of sodium salt of C₈₋₁₈ fatty

acid, sodium salt of bile acid, sodium alginate, and sodium carboxymethylcellulose, or a cationic

compound selected from the group consisting of carnitine salt, benzalkonium chloride and

cetrimide;

(b1) adding a lipid, a polymer and a solubilizing agent to the complex obtained from step

(a) and dissolving them, and adding the obtained solution to an aqueous solution containing an

emulsifier, to obtain a homogeneous liquid phase, or

(b2) adding a lipid and a solubilizing agent to the obtained complex and dissolving them,

and adding the obtained solution to an aqueous solution containing a polymer and an emulsifier,

to obtain a homogeneous liquid phase; and

(c) eliminating the solubilizing agent from the mixture obtained from step (b1) or (b2).

21. (Withdrawn) The method of Claim 20, further comprising step (d) of minimizing the

Amendment dated August 20, 2008

Reply to Office Action of April 23, 2008

particle size using a microfluidizer.

22. (Withdrawn) The method of Claim 20, wherein the charged water-soluble drug is

obtained by treating the water-soluble drug with a pH adjusting agent to confer charge thereon in

step (a).

23. (Withdrawn) The method of Claim 22, wherein the pH adjusting agent is selected

from the group consisting of hydrochloric acid, phosphoric acid, carbonic acid, citric acid,

sodium hydroxide, sodium/potassium monohydrogen phosphate, sodium/potassium dihydrogen

phosphate, sodium phosphate, sodium citrate, and mixtures thereof.

7

Docket No.: 1599-0331PUS1